Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial.

Autor: Ter Veer E; a Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Oncology, Academic Medical Center , Meibergdreef 9 , Amsterdam , the Netherlands., Prinsen H; b Department of Radiology and Biomedical Imaging , Yale University , New Haven , Connecticut , USA., Sprangers MAG; c Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Psychology, Academic Medical Center , Meibergdreef 9 , Amsterdam , the Netherlands., Zwinderman KAH; d Amsterdam University Medical Centers, University of Amsterdam, Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Meibergdreef 9 , Amsterdam , the Netherlands., Bleijenberg G; e Expert Centre for Chronic Fatigue , Radboud University Nijmegen Medical Centre , Nijmegen , the Netherlands., van der Pouw Kraan TCTM; f Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Molecular Cell Biology and Immunology , VU University Medical Center , Amsterdam , the Netherlands., de Vries IJM; g Department of Tumor Immunology , Radboud University Nijmegen Medical Centre , Nijmegen , the Netherlands., Wierenga EA; h Amsterdam University Medical Centers , University of Amsterdam, Department of Experimental Immunology, Academic Medical Center , Amsterdam , the Netherlands., van Laarhoven HWM; a Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Department of Medical Oncology, Academic Medical Center , Meibergdreef 9 , Amsterdam , the Netherlands.
Jazyk: angličtina
Zdroj: Cancer investigation [Cancer Invest] 2018; Vol. 36 (7), pp. 371-377. Date of Electronic Publication: 2018 Sep 06.
DOI: 10.1080/07357907.2018.1499933
Abstrakt: We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker.
Trial Registration: This study is registered at ClinicalTrials.gov (NCT01096641).
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje